Latest Erythropoietin Stories
DUBLIN, March 28, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/8zbxmj/investigation) has announced the addition of the
ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Epoetin Alfa Market, 2009-2018” to its store. Dallas, TX (PRWEB) March
The CKD Market Will Decline Through 2017, Due to Genericization of Expensive Agents and Reimbursement Constraints in the U.S., According to Findings from Decision Resources Group BURLINGTON,
In recent years, non-hematopoietic effects of erythropoietin (EPO), via its binding to the EPO receptor in non-hematopoietic tissues, including cancerous tissues, has been reported by many different laboratories worldwide.
MarketResearchReports.Biz announces addition of new report “Chemotherapy Induced Anemia - Pipeline Review, H2 2013” to its database.
Medical Food Designed to Address the Increased Nutritional Requirements of Anemia Los Angeles, CA (PRWEB) September 04, 2013
In patients with high-risk breast cancer, addition of the erythropoiesis-stimulating agent (ESA) epoetin alfa to the chemotherapy regimen may help avoid the decrease in hemoglobin levels and resulting anemia often seen in these patients and does not negatively affect relapse-free (RFS) or overall survival (OS).